Trial Profile
A randomized, prospective, cross-over, double blind, placebo-controlled multicentre study to assess the efficacy and tolerability of almotriptan 12.5 mg in the mild pain phase of Mestrual Migraine followed by an open follow-up evaluation to assess consistency
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 13 Jun 2011
Price :
$35
*
At a glance
- Drugs Almotriptan (Primary)
- Indications Menstrual migraine
- Focus Therapeutic Use
- Sponsors Almirall S.A.
- 13 Jun 2011 New source identified and integrated (European Clinical Trials Database).
- 05 Nov 2010 New trial record.